Puma Biotech (PBYI) Is Attractively Priced Despite Fast-paced MomentumZacks Investment Research • 01/22/24
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology ConferenceBusiness Wire • 01/11/24
Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain StockZacks Investment Research • 01/03/24
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast CancerBusiness Wire • 12/11/23
Here Is Why Bargain Hunters Would Love Fast-paced Mover Puma Biotech (PBYI)Zacks Investment Research • 12/01/23
Puma Biotech (PBYI) Loses -18.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/20/23
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial ResultsBusiness Wire • 10/19/23
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics MeetingBusiness Wire • 10/14/23
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung CancerBusiness Wire • 09/21/23